Introduction
Cystinosis is a rare systemic lysosomal storage disease which, if not treated, leads to end-stage kidney failure in the first decade of life. 1 Its natural history has been transformed thanks to the development of kidney transplantation (KTx) in children 2 and the availability of specific treatment with cysteamine, a drug therapy that should be maintained throughout the patient's lifetime. 3 As a consequence, patient survival has increased from the first decade of life to beyond the fourth decade and cystinosis has passed from paediatrics to adult medicine. 4 The control of cystinosis is complex owing to its severity and multisystemic nature, and the requirement of treatment with several drugs with a very strict dosage schedule. Early diagnosis, prompt cysteamine administration and treatment adherence influence morbidity and prognosis. 5, 6 Nevertheless, adherence to therapy, which is usually good in children, tends to wane in teenagers and adults. 7 Furthermore, when patients reach adult age, they are usually transferred from the paediatric expert centre to a local hospital with limited experience in cystinosis, while the systemic manifestations continue to progress and the disease becomes more complex. 8 This phenomenon is seen in other chronic renal diseases that debut in paediatric patients 9 and highlights the need to implement transition strategies and promote patient self-care. 10 The current cystinosis count in Spain comprises 56 patients treated and followed up at 22 hospitals. Approximately 50% are adults and 16% adolescents; 57% are kidney transplant recipients. 7 The working group for the care and transition of cystinosis in Barcelona (T-CiS.bcn) has assembled a group of experts in the disease to establish, as a first step, recommendations for the comprehensive care of cystinosis and the transition of adolescents to adult-care units in our country. This consensus document presents a support tool for health care professionals both involved in and interested in cystinosis. It is focused on reducing disease impact, improving quality of life and prolonging survival, in accordance with the guidelines of the International Society of Nephrology (ISN) and the International Paediatric Nephrology Association (IPNA). 10 At a later date, the T-CiS.bcn group plans to create a coordinated model of transition from paediatric to adult care services which will cover the specific needs of cystinosis.
Etiopathogenesis
Cystinosis is a hereditary autosomal recessive disease caused by mutations with loss of function of the CTNS gene (chromosome 17p13), which encodes for cystinosin. 11 Cystinosin is a specific transmembrane protein for the transport of cystine from the lysosome to cell cytoplasm. 12 Its absence causes progressive deposits of intralysosomal cystine, the main diagnostic marker of the disease 1 . Its annual incidence is estimated at 1/100,000-200,000 newborns, while the population prevalence is 1-9/1,000,000. 13 The most frequent mutation in the CTNS gene is a deletion of 57 Kb 14 which is also observed in 34% of patients in the Spanish population. 15 The amino acid cysteine oxidises inside the lysosome and forms cystine. In patients with cystinosis, there is an accumulation of cystine that precipitates in crystal form in all the cells of the organism, particularly in renal and ocular tissue. 16 The increase in the lysosomal concentration of cystine is associated with increased cellular apoptosis, oxidative stress and alterations in the metabolism of glutathione and arachidonic acid. [17] [18] [19] Other pathogenic mechanisms involved are inflammatory 20 and "endoplasmic reticulum stress", which finally lead to cell death. 21, 22 Symptoms Cystinosis is a multisystemic disease 23 with the kidneys and eyes being the first organs to be affected. Three clinical forms have been described: infantile nephropathic cystinosis (OMIM#219800), the most serious subtype, which debuts early on; juvenile nephropathic cystinosis (OMIM#219900), a less severe subtype, which debuts in childhood or later; and adult non-nephropathic cystinosis (OMIM#219750), with exclusively ocular involvement. 24 Nonetheless, in clinical practice, two main subtypes are defined: nephropathic cystinosis that debuts in early childhood with severe Fanconi syndrome (representing 95% of all cases) and late-onset non-nephropathic cystinosis, which appears in young patients or adults with renal and/or ocular involvement (representing <5% of affected patients). In some patients, ocular involvement can precede renal manifestations by several years. 25 
Renal disease

Fanconi syndrome
Typical clinical symptoms include the appearance of severe Fanconi syndrome with evolution to chronic kidney disease (CKD) (Fig. 1) . Tubulopathy characteristically becomes evident in the second semester of life after a symptom-free interval. 24 Affected newborns are apparently normal, although it is possible to detect urinary alterations (alkalineurine with glycosuria and/or proteinuria) very early preceding symptoms. 26 Cystinosis is the most frequent cause of inherited Fanconi syndrome 24 and should be considered in the initial differential diagnosis in newborns. Nonetheless, cases have been described of cystinotic patients who debuted with atypical symptoms not suggestive of Fanconi syndrome but of distal tubulopathy, such as nephrogenic diabetes insipidus or Batter syndrome. Thus, the diagnosis of cystinosis should be considered in all newborns with complex tubulopathy, particulary if growth is affected and the patient is anorexic. 1 The differential diagnosis should contemplate the possibility of secondary proximal tubulopathy. 27, 28 The severity of Fanconi syndrome associated with cystinosis requires rigorous treatment that is frequently very complex (Table 1) .
Chronic kidney disease
After the age of two, if no specific treatment is administered, glomerular involvement progress with a drop in the glomerular filtration rate (GFR) and an increase in plasma creatinine starting at the age of 4 to 6, which evolves to advanced CKD. 1 Concurrently, Fanconi syndrome usually remits and, consequently, it is possible to reduce water/electrolyte supplements (Table 1 ). In the absence of specific pharmacological treatment (cysteamine), mean age at the onset of end-stage renal disease (ESRD) is 9.2 years. In more contemporary series including patients who received early treatment with cysteamine, there is a significant delay in evolution to ESRD at the age of 13.5 which has been attributed to better patient control by physicians. Furthermore, in cases with very early diagnosis and treatment, there is a growing percentage of patients who remain in predialysis after adolescence. 6 F ig.1-Clinical manifestations of cystinosis in patients not treated with cysteamine. CKD: chronic kidney disease, ESRD: end stage renal disease, RRT: renal replacement therapy.
There are also forms of attenuated or late-onset cystinosis that debut in adolescence or in young adults, such as glomerular disease and proteinuria without Fanconi syndrome, although occasionally signs suggestive of proximal tubulopathy are observed. Usually, patients also present ocular manifestations of the disease that can be nearly asymptomatic 25 (Fig. 1) .
Although renal biopsy is not necessary for diagnosis, it demonstrates non-specific lesions of glomerulosclerosis and other more characteristic signs such as irregularities on the brush border of proximal tubule cells, swan neck deformity and, occasionally, deposits of cystine crystals and giant multinucleated podocytes. 2, 16, 24 
Dialysis
The renal replacement therapy (RRT) of choice in cystinosis is the kidney transplantation (KTx) since the disease does not recur in kidney grafts. In many cases, however, the limitation of organs or delayed diagnosis results in the start of dialysis. According to the NAPRTCS register, 1.4% of patients <18 years of age who initiated chronic dialysis had cystinosis. 30 On the other hand, in the European ESPN/ERA-EDTA Registry, 0.9% of patients <20 years of age and 0.1% of patients >20 years with RRT had cystinosis. In Europe, peritoneal dialysis (PD) was the most frequent initial treatment modality (39.6%), followed by preventive KTx (35.1%). Some 17.9% of patients received haemodialysis (HD). 5 Fanconi syndrome can persist after the start of dialysis, which influences the dietetic prescription for water, patient diet and the possible need to administer other medications such as phosphorus chelates. Although the urinary loss of saline and polyuria usually decrease in advanced CKD, the patient may continue to need water/electrolyte supplements and carnitine (Table 1) . On rare occasions, the severity of Fanconi syndrome justifies nephrectomy of the native kidneys. 31 Moreover, many cystinotic patients on dialysis characteristically present extrarenal involvement requiring the integrated intervention of other specialists (see section on extrarenal involvement), which can be a challenge for nephrologists when treating their patients. 32 
Kidney transplantation
As previously stated, the RRT of choice in cystinosis is KTx. Since graft cells do not carry the lysosomal defect, the disease does not recur in the transplanted organ. However, it is possible to observe interstitial deposits of cystine crystals, which represent leukocytes of the recipient and have no pathological significance. 21 Family-donor transplantation is also curative, and heterozygous carriers of the CTNS mutation can be appropriate donors since they do not have the disease. 4, 6, 33 Indirect data from cystinotic patients with advanced kidney failure and international registries suggest that preventive kidney transplantation would be beneficial in this disease, particularly when a living donor is available 4 thereby avoiding the need for dialysis. 5 Thus, the indication for kidney transplantation is established when the GFR is <20 ml/min/1.73 m 2 , which would be somewhat earlier than in other kidney diseases. 1 In the United States (USRDS2013), mean age of patients with cystinosis at the first KTx is 13.8 years (range: 2 to 24), 34 Similarly, in Europe 48.9% received a living donor transplant. 5 It is worthy of mention that the duration of functioning kidney grafts in cystinotic patients is longer than that observed in the population of recipients transplanted for other causes. 5, 35 
Extrarenal disease
The longer survival and better prognosis of patients with cystinosis have resulted in better understanding of the multiple organ involvement in this disease 4, 6, 32, 36 (Fig. 1) .
Ocular involvement
Eye involvement is intrinsic to cystinosis. The presence of cystine crystals in the cornea is a diagnostic criterion for this disease, 37 although its absence before the age of 12 months may not rule it out. 1 Cystine deposits in the cornea are one of the earliest manifestations of cystinosis (Fig. 1) . Although no crystals are present at birth, they can be observed in children who are only a few months old. 1 Initially, they are deposited in the superficial layers of the peripheral cornea, but progressively begin to affect all the layers and entire extension of the cornea. If left untreated, corneal crystal deposits progress inexorably, increasing with age, resulting in photophobia, which can be quite incapacitating, and in abnormal corneal sensitivity. In time, this condition leads to recurrent corneal erosions and stromal oedema, which can reduce visual acuity. Reports also exist of calcium deposition in Bowman's membrane or band keratopathy, which affect vision when situated in the visual axis. 37 Crystals are also deposited in other ocular structures such us the conjunctiva, anterior chamber, iris, ciliary body, choroid and retina. Retinal involvement causes degeneration of the photoreceptors, mainly the rods, thereby altering the peripheral visual field and night vision, although central vision may also be reduced. Less frequently, there have been reports of posterior synechiae, adherence of the iris to the anterior lens capsule and neovascularisation of the peripheral cornea. 38, 39 Furthermore, tear production is reduced, causing dry eye, and neuro-ophthalmological manifestations (papilledema and ophthalmoplegia) are observed secondary to the increased intracranial pressure reported in this disease. 4 In late-onset disease, the presence of crystals might not be detected until adulthood. 25 
Growth and development: mineral-bone involvement
Failure to thrive is a classic clinical symptom of cystinosis and frequently is the reason for an early consultation. 36 The underlying mechanism is multifactorial, although it is related to Fanconi syndrome severity. The concurrence of metabolic acidosis, hyponutrition, increased gastrointestinal and renal losses and CKD lead to delayed growth that can be very severe. 40, 41 Similarly, patients present endocrine alterations (see endocrine involvement section) and, infrequently, primary growth hormone (GH) deficiency. 42 Patients with inadequate treatments usually have shorter stature. 36 Classically, the adult height reported in patients with suboptimal treatment is 144 cm and weight 45 kg (25 cm and 25 kg below the normal population average, respectively). 4 The most recent series with better therapeutic control reported less retarded growth 8 and a favourable impact of treatment on growth regulation mechanisms. 43 Nevertheless, nowadays 27% of transplanted cystinotic patients and 44% of those on dialysis continue to be shorter than average. 5 Early GH administration improves height and weight, although the therapeutic response is usually lower than that observed in CKD due to other causes, despite optimum disease control. GH is an essential therapeutic tool in this disease, for its impact on longitudinal growth and its anabolic effect. 40, 44 Patients with cystinosis develop a characteristic metabolic bone disease caused by different factors: bone deposits of cystine crystals, mineral deficiency, renal rickets 24 and CKD per se. 45 Bone anomalies attributed to copper deficiency, possibly secondary to Fanconi syndrome have also been described. 46 It is therefore common to detect osteopenia, especially in trans-plant recipients, related also to other endocrine alterations of the disease (see endocrine involvement section) and potentially to the treatment. 23, 47 Some patients have bone fragility and a higher risk of fractures. 32 
Endocrine involvement
Endocrine manifestations are caused by destruction of the affected glands due to cystine deposits; their incidence and age at appearance are associated with the establishment of specific treatment with cysteamine. 43 Primary hypothyroidism is the most frequent endocrine complication; 23 it is progressive and requires chronic treatment with levothyroxine. 1, 4 Diabetes mellitus (DM) is characterised by a progressive alteration in insulin secretion, 48 with negative immunology, and requires treatment with insulin. 2 It is observed in transplant recipients who receive corticosteroids. 23 In males, cystinosis causes primary hypogonadism and infertility is a constant. 4, 49 In females, however, neither hypogonadism nor infertility are prevalent, and affected patients can thus have children, 50 although the risk of prematurity is increased. 51 
Cardiovascular involvement
The appearance of dyslipidemia and vascular calcification due to cystinosis and CKD are considered increased cardiovascular risk factors. 23, 32, 41 42% of patients develop arterial hypertension, usually post-transplantation. Aortic aneurysms and coronary vessels involvement, as well as cardiomyopathy associated with cystine crystals deposits in the myocardium have also been reported. 36 In adult patients, screening for ischaemic heart disease is recommended. 4 
Neurological involvement
Cystinosis is associated with alterations in cerebral structure and increased cystine levels in different areas of the nervous system and muscle tissue. 4, 6, 32, 52 In general, neurological complications worsen the prognosis of the disease:
• Progressive ischaemic myopathy 4, 32, 53 is predominantly distal and begins in the hands; loss of muscle mass is also observed with later ventilator capacity impairment and swallowing difficulties. Some authors attribute muscle weakness in these patients to carnitine deficiency. 24, 28, 29 • Central nervous system (CNS) involvement 4,31 is mainly observed in patients with suboptimal treatment with cysteamine: -Acute presentation: epilepsy, stroke, encephalopathy, cephalalgia 54-57 -Subacute/progressive presentation: intracranial hypertension, cerebral atrophy, ataxia, pyramidalism, gait disorders, basal and periventricular lymph node calcifications, demyelination of white matter, mental deterioration [58] [59] [60] [61] [62] [63] [64] [65] [66] • Neurocognitive alterations: [67] [68] [69] [70] [71] [72] [73] in cystinotic patients, a specific profile of alterations in visual-motor integration, visual memory, maintained attention, planning, motor processing speed and arithmetic calculation have been described. Consequently, they account for a significant incidence of social difficulties that could explain the behavioural phenotype in some patients. Intelligence is usually normal.
Early detection of neurological complications in cystinosis facilitates better therapeutic strategies, reduces the number of hospitalisations and improves quality of life. The participation of a neurologist will help to evaluate the functional capacity of patients and detect earlier the neurological manifestations that can affect autonomy in basic daily life activities. 8, 31, 32, 55 
Miscellaneous
The ubiquity of cystinosis is demonstrated by its non-specific symptoms e.g. gastrointestinal and other disorders such as heat intolerance and hypophoresis. Similarly, the systemic nature of the disease explains the progressive appearance of other clinical symptoms secondary to the deposition of cystine crystals in different organs and systems, as detailed below ( Fig. 1 ):
• Digestive system 74 : -Nausea, vomiting, epigastralgia, anorexia -Increased gastrin secretion (associated with taking cysteamine) -Decreased salivation -Mechanical swallowing difficulties -Delayed gastric emptying and intestinal and intestinal dysmotility -Intestinal pseudo-obstruction -Intestinal inflammatory disease
• Liver 32, 75 :
-Regenerative nodular hyperplasia without liver failure -Non-cirrhotic portal hypertension with hypersplenism -Cholestasis -Hypercholesterolemia
• Skin 1,76 : -Hypopigmentation of skin and hair due to altered melanogenesis -Altered sweating and intolerance to heat
• Bone marrow 4 :
-Anaemia -Coagulopathy due to dysfunctional platelets
Diagnosis
The clinical diagnosis of cystinosis is symptom-based and is confirmed by biochemical and molecular diagnosis.
Clinical diagnosis
Guiding signs are early-onset of severe Fanconi syndrome and the detection of corneal crystals. As the disease progresses, systemic involvement may be observed (Fig. 1) . However, in patients with less severe forms, renal involvement is restricted to proteinuria and CKD. Occasionally, corneal crystals in adult patients with CKD of unknown aetiology lead to the diagnosis of cystinosis. 25 Kidney biopsy, while not a requirement for the diagnosis of cystinosis, can be useful in these atypical presentations. 
General biochemical diagnosis
This diagnosis is based on the detection of water/electrolyte disorders, affected acid-base balance and eventually renal function, which are all prototypical of Fanconi syndrome. 24, 28 
Specific biochemical diagnosis
This involves the detection of elevated white blood cells (WBC) cystine levels. 77 Currently High Performance Liquid Chromatography-Tandem Mass Spectrometry (HPLC-MS/MS) in granulocytes is used as it is a more sensitive technique. 78, 79 The reference values are:
• healthy individual: ≤0.5 nmol 1/2 cystine/mg protein (values >0.5 may have diagnostic significance, and it is recommended to repeat the determination)
• affected individual without treatment: >1 nmol 1/2 cystine/mg protein (usually >2)
• individual treated with good therapeutic control: ≤1n m o l 1/2 cystine/mg protein Normal WBC cystine levels in newborns do not completely rule out the diagnosis. Therefore, in cases where cystinosis is highly suspected, a second test is recommended 3-6 months after the first study when the results are not conclusive 79 ( Table 2 ).
Molecular diagnosis
Cystinosis is confirmed by the detection of homozygous or compound heterozygous mutations in the CTNS gene. More than 100 different mutations have been reported and the most frequent one is the ∼57 kb deletion affecting the first 10 exons, especially in patients of Northern European descent. Specific mutations turn into an absence of protein or a probably nonfunctional truncated protein 11, 12, 14, 15, 80 (Table 2) .
Genetic counselling
Since cystinosis is an autosomal recessive disease, the probability of a family with one affected child having another with cystinosis is 25%. 81 In this case, genetic counselling includes information on prenatal diagnostic techniques and embryo selection. 82, 83 The probability of a woman with cystinosis having an affected child is very low, except in consanguineous families or endogamous populations. Males with cystinosis are universally sterile. 49 Genetic counselling usually includes information on patient associations [84] [85] [86] and institutional strategies in rare diseases. 87 
Treatment
Symptomatic treatment of kidney involvement
The aim of treatment (Table 1 & Annex 1) is to control Fanconi syndrome, its complications and other factors involved in kidney failure progression. [24] [25] [26] [27] [28] In ESRD, promoting KTx is a priority. Regardless of kidney involvement, all patients should receive specific treatment with cysteamine for the prevention and therapeutic control of the systemic disease.
Treatment of CKD should follow international guidelines. [88] [89] [90] In transplanted patients, minimising or avoiding corticosteroids use is recommended. 23 
Specific treatment with cysteamine
Oral cysteamine
The specific treatment for all clinical forms of cystinosis is oral cysteamine. Cysteamine depletes lysosomal cystine content by forming disulphide cysteine-cysteamine complexes able to exit the lysosomes by means of the alternative lysine channel, and the remaining cysteine via a cysteine carrier. 3, 19, 91 The first specific pharmacological treatment for cystinosis is Cystagon ® (oral cysteamine bitartrate in hard capsules), the only authorised therapy in Spain [92] [93] [94] . A new formula in hard gastro-resistant capsules has recently been approved for cysteamine. [93] [94] [95] [96] 
Therapeutic benefits
Oral cysteamine should be initiated at the time of diagnosis and continued lifelong. When compliance is consistent, cysteamine is able to deplete up to 95% of cellular cystine deposits. 62 The reduction in these deposits correlates with cystinosis severity. 32 It has been demonstrated that cysteamine prolongs the life of the patient, while delaying kidney disease progression and the need for renal replacement therapy. 5, 97 Similarly, it reduces the severity and frequency of extrarenal complications. 32 Prognosis of the disease is directly related to early treatment and its duration. Even when cystinosis diagnosis is delayed, cysteamine has demonstrated clinical benefits. 4, 6, 98 Although Fanconi syndrome is not usually reversible with cysteamine, 19 in some isolated cases of prenatal diagnosis the beginning of cysteamine therapy within the first weeks of life prevented the appearance of tubulopathy. 99, 100 Cystagon
® : dosage, administration and treatment monitoring
Treatment is based on the depletion of lysosomal cystine content which, in clinical practice, means the reduction of WBC cystine levels, with an optimal therapeutic goal <1 nmol hemicystine/mg of protein. The decrease in those WBC cysteine levels correlates with plasma cysteamine concentrations for the 6 hours following Cystagon ® dose, being minimum at ∼2h after the drug is taken and returning to baseline (pre-dose) 6 h later. This explains the need to take the drug every 6 h, overnight dose included 101, 102 (Table 3) .
Monitoring of WBC cysteine levels at the start of treatment and monthly after changes in the prescribed dosage is recommended. In patients with maintained cystine levels, follow-up controls are recommended every 6 months. Similarly, in an individualised manner, the frequency of monitoring should be increased in case of significant clinical changes such as KTx and dialysis 77, 78, 79 (Table 2) .
Oral treatment in special situations
Chronic kidney disease, dialysis and transplantation
Since there is no correlation between GFR and plasma cysteamine levels, it is not necessary to adjust the dosage to renal function; instead, the prescribed dosage should be adjusted to the quantification of WBC cystine levels. Adjustments for Fanconi syndrome are also unnecessary. 6, 103 
Pregnancy and breastfeeding
Although data is insufficient, reproductive toxicity and teratogenic effects of cysteamine have been observed in animals. 104 Its use is therefore contraindicated during pregnancy, particularly in the first trimester. Family planning is recommended in women of childbearing age. Furthermore, cysteamine administration should be avoided during breastfeeding.
Cysteamine eye drops
Specific treatment of ocular involvement in cystinosis requires, in addition to oral cysteamine, the use of cysteamine eye drops. The ophthalmological therapeutic strategy 32, 37 makes a distinction between:
Corneal involvement
Cystine crystal deposits should be treated with topical cysteamine since the cornea is an avascular structure and, consequently, oral medication is not effective for the cornea. 37, 38, 105, 106 The recommended prescription is shown in Table 3 . Viscous formulae are being developed to achieve longer contact of cysteamine with the ocular surface and be able to reduce the frequency of instillations with equal efficacy. 107, 108 
Involvement of non-corneal structures
Oral cysteamine is effective in the retina and other ocular structures. The incidence of retinopathies has decreased with the systemic use of cysteamine. The frequency and severity of non-corneal manifestations are directly related to compliance with oral cysteamine treatment, and the risk of important vision loss may arise if systemic treatment is not correctly followed. 39, 109 Compliance with specific cysteamine treatment
The World Health Organization (WHO) defines compliance as the degree to which patient behaviour follows the recommendations of medical professionals. 110 The impact of non-adherence in cystinosis results in poorer prognosis and faster progression of the renal and extrarenal Recommendations for dialysis 6, 103 Promote preventive KTx as an initial method of RRT in patients with advanced CKD Monitor residual urine volume and urinary saline loss to adapt the dialysis prescription and avoid excessive ultrafiltration Maintain the general treatment of Fanconi syndrome and adapt the diet in an individual manner Carefully monitor extrarenal involvement on a multidisciplinary basis Oral and ophthalmological cysteamine treatment must be maintained Cysteamine dosage should not be adjusted to glomerular filtration rate (see Specific Treatment with Cysteamine section)
Recommendations for kidney transplantation [4] [5] [6] 33, [88] [89] [90] Prior to waiting list inclusion Promote preventive kidney transplantation when the glomerular filtrate ≤20 mL/min/1.73 m In any clinical situation, it is necessary to administer specific cystinosis treatment with oral cysteamine to maintain recommended WBC cystine levels <1 nmol hemicystine/mg protein and cysteamine eye drops to eliminate corneal deposits (see Table 3 ). In any clinical situation, specific cystinosis treatment is required with oral cysteamine to maintain recommended WBC cystine levels <1 nmol hemicystine/mg protein and cysteamine eye drops to eliminate corneal deposits (See Table 3 ).
ERG: electroretinogram; GH: growth hormone; VA: visual acuity. * Very sensitive for diagnosing cystine crystals in the cornea, but less useful for patient follow-up since the quantification of crystals is rather subjective. It is therefore interesting to record detailed data at each examination on the distribution of crystals in the cornea, specifying whether the deposition is only peripheral or diffuse and whether they are located in the epithelium, stroma and/or endothelium. In any clinical situation, specific cystinosis treatment is required with oral cysteamine treatment to maintain recommended WBC cystine levels <1 nmol hemicystine/mg protein and topical cysteamine to eliminate corneal deposits.
25OHD3: 25-hydroxycholecalciferol (calcifediol); FSH: follicle-stimulating hormone; GH: growth hormone; HbA1c: glycated haemoglobin; IGF-1: insulin-like growth factor 1; IGFBP3: insulin-like growth factor-binding protein 3; LH: luteinising hormone; PTH: parathyroid hormone; rGH: recombinant growth hormone; SHBG: sex hormone-binding globulin; T: testosterone; T4: free thyroxine; TG: triglycerides; TSH: thyroidstimulating hormone. disease in patients who are non-compliant compared with those who are. 5, 6, 97 Information on adherence in patients with cystinosis is limited, although monitoring WBC cystine levels is able to detect non-compliant patients. 77, 79 Other studies have confirmed adequate adherence to Cystagon ® in children patients which wanes significantly in adolescents and adults. 7, 8 Nonetheless, in groups of highly motivated patients, only 8% had compliance problems. 111 In cystinosis, risk factors for non-compliance with cysteamine therapy include: dosage schedules, problems with tolerance, side effects and the requirements of several medications for the control of the clinical manifestations of the disease. Moreover, other risk factors which are not exclusive to cystinosis are: limited knowledge of the disease, lack of motivation, inadequate transition of patients to adult care units and impact of the disease on quality of life. 7, 9, 10 Nevertheless, suboptimal treatment compliance is not a phenomenon restricted to cystinosis. Recent studies report that 52 to 67% of adult kidney transplant recipients do not correctly follow prescribed immunosuppressant treatment, which increases the probability of graft loss. 112, 113 These percentages are similar to those published in patients with cystinosis in our population, 7 which may indicate the coexistence of scenarios in common with CKD. Therefore, in order to improve adherence in cystinotic patients, the recommended strategy is to correct risk factors for non-compliance and promote patient self-care, similar to the strategies used successfully in adult kidney transplant recipients [114] [115] [116] [117] [118] [119] (Table 4) .
Recommendations for the follow-up and treatment of patients with cystinosis T-CiS.bcn group members, after an exhaustive review of medical literature and based on our clinical practice with patients, have stablished recommendations for the multidisciplinary care and connected transition from paediatric to adult-care units in cystinosis. Our aim was to provide support tools and medical advice to health care professionals involved and interested in the care of cystinosis.
These recommendations are presented in Tables 4-8 . In any clinical situation, specific cystinosis treatment is required with oral cysteamine treatment to maintain recommended WBC cystine levels <1 nmol hemicystine/mg protein and topical cysteamine to eliminate corneal deposits. 
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Phosphorus supplements
Sodium Phosphate *Phosphorus oral solution or Joulie Solution 1 mmol P/ml (30.9 mg P/ml) Phosphate Sandoz 500mg (100 cap.)
16.1 mmol P/comp (500 mg P/comp.) Sodium Phosphate monobase NM (100 sachets) 26 mmol P/sobre (800 mg P/sachet) *Polycitra LC with phosphrous-oral solution 2 mEq Bicarbonate; 1 mEq Na/mL; 1 mEq K/mL; 1 mmol Citrate/mL; 0.6 mmol P/mL) Others Carnitine Carnicor 1.5 g/5 mL (40 mLoral solution) 300 mg/mL carnitine Carnicor 1 g drinkable vials (10 mL) 100 mg/mL carnitine Secabiol 300 mg/mL (40 
